Dubois Stringfellow Nathalie Insider Trades

Insider Trading History

Track insider trading activity for Dubois Stringfellow Nathalie. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $24k 328,733 shares
Last Trade
May 25, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$686 4,036 shares
$0.17
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $24.3k 332,769 shares
Last Trade
Apr 21, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$89.9k 345,942 shares
$0.26
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $58.5k 800,000 shares
Last Trade
Apr 01, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$208k 800,000 shares
$0.26
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $49.6k 678,711 shares
Last Trade
Feb 25, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$5.81k 12,354 shares
$0.47
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $50.5k 691,065 shares
Last Trade
Feb 24, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$970 2,063 shares
$0.47
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $50.7k 693,128 shares
Last Trade
Jan 22, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$14.7k 36,676 shares
$0.40
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $52.6k 719,804 shares
Last Trade
Nov 24, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.07k 2,544 shares
$0.42
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $52.8k 722,348 shares
Last Trade
Oct 22, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$28.9k 43,741 shares
$0.66
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $56k 766,089 shares
Last Trade
Aug 24, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.06k 1,792 shares
$0.59
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $56.1k 767,881 shares
Last Trade
Jul 22, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$15.3k 31,866 shares
$0.48
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $58.5k 799,747 shares
Last Trade
May 24, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$842 1,792 shares
$0.47
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $58.6k 801,539 shares
Last Trade
Apr 22, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$24.9k 31,866 shares
$0.78
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $60.9k 833,405 shares
Last Trade
Feb 25, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$538k 560,000 shares
$0.96
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $52.1k 713,405 shares
Last Trade
Feb 25, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.45k 1,513 shares
$0.96
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $52.3k 714,918 shares
Last Trade
Feb 24, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.79k 1,792 shares
$1.00
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $52.4k 716,710 shares
Last Trade
Jan 22, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$149k 129,593 shares
$1.15
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $61.5k 841,303 shares
Last Trade
Nov 25, 2024 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$2.93k 1,508 shares
$1.94
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $61.6k 842,811 shares
Last Trade
Nov 24, 2024 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$3.36k 1,787 shares
$1.88
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $61.7k 844,598 shares
Last Trade
Aug 25, 2024 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.3k 1,508 shares
$0.86
$0.07
Sangamo Therapeutics
Sangamo Therapeutics SGMO
Svp-chief DEVELOPMENT OFFICER
Holding Value $61.9k 846,106 shares
Last Trade
Aug 24, 2024 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.54k 1,787 shares
$0.86
$0.07

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up